Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ...
VYNE Therapeutics Inc. (VYNE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...
Vyne Therapeutics Inc. VYNE shares are trading higher Monday after the company announced a private placement of $88 million and positive data from its Phase 1b trial. In addition to the $88 million ...
Vyne Therapeutics (NASDAQ:VYNE) stock rose ~10% premarket on Wednesday after the company said preclinical data showed positive effect of inhaled formulation of VYN201 in a mouse model of idiopathic ...
BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated ...
FDA places clinical hold on VYNE’s Phase 1b trial of VYN202 due to testicular toxicity seen in preclinical dog study. VYNE halts enrollment and dosing in psoriasis study; no serious adverse events ...
VYNE Therapeutics (NASDAQ:VYNE) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach. H.C. Wainwright analyst Joseph Pantginis is behind today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results